Literature DB >> 9804658

Endothelial cell culture from human cerebral cavernous malformations.

N I Baev1, I A Awad.   

Abstract

BACKGROUND AND
PURPOSE: The cerebral cavernous malformation (CCM) is a common and frequently unrecognized cause of stroke and epilepsy. It consists of blood-filled caverns lined by endothelial cells (EC) and devoid of mature vessel wall structure. Cultured EC obtained from CCM may express phenotypic and genotypic alterations contributing to CCM pathogenesis. We report the first successful isolation and growth in vitro of primary EC lines from human CCM lesions.
METHODS: We developed a procedure for the isolation and growth of EC from human CCM, confirmed their EC origin by a panel of molecular markers, and determined by immunocytochemistry the basic expression patterns of 6 transmembrane receptor protein kinases comparing brain, skin, and CCM primary EC lines grown identically.
RESULTS: Several CCM EC lines were established from 2 patients after we treated the excised specimens with 0.3% trypsin/1% EDTA, selective cloning, and growth in MCDB107 containing 0.3 g/L heparin, 0.15 g/L endothelial cell growth supplement, and 15% FBS. The CCM EC showed contact inhibition and a rounded cobblestone appearance. The cells expressed CD31, CD105, von Willebrand factor, and binding sites for Ulex europaeus agglutinin, type 1 and acetylated LDL. They showed low levels of Flt-1, Flk-1, transforming growth factor (TGF)-beta RI, and TGF-beta RII expression but stained strongly with antibodies against Tie-1 and Tie-2.
CONCLUSIONS: Cultured CCM EC retained their endothelial phenotype. Brain, skin, and CCM EC lines did not significantly differ in their staining patterns with antibodies against Flt-1, Flk-1, TGF-beta RI, TGF-beta RII, Tie-1, and Tie-2. These cell lines will assist in defining molecular phenotype and genotype alterations in association with CCM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804658     DOI: 10.1161/01.str.29.11.2426

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  Systems biology and proteomic analysis of cerebral cavernous malformation.

Authors:  Alexander R Edelmann; Sarah Schwartz-Baxter; Christopher F Dibble; Warren C Byrd; Jim Carlson; Ivandario Saldarriaga; Sompop Bencharit
Journal:  Expert Rev Proteomics       Date:  2014-03-31       Impact factor: 3.940

2.  Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades.

Authors:  Sabine Miebach; Stefan Grau; Vera Hummel; Peter Rieckmann; Joerg-Christian Tonn; Roland Helmut Goldbrunner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

3.  Cavernous malformations of the orbit: a distinct entity? A review of own experiences.

Authors:  Nedal Hejazi; Werner Hassler; Felix Offner; Antonius Schuster
Journal:  Neurosurg Rev       Date:  2006-11-07       Impact factor: 3.042

4.  Differential gene expression in human cerebrovascular malformations.

Authors:  Robert Shenkar; J Paul Elliott; Katrina Diener; Judith Gault; Ling-Jia Hu; Randall J Cohrs; Tzulip Phang; Lawrence Hunter; Robert E Breeze; Issam A Awad
Journal:  Neurosurgery       Date:  2003-02       Impact factor: 4.654

5.  Temporal expression analysis of angiogenesis-related genes in brain development.

Authors:  Abdulkadir Ozkan; Atilla Biçer; Timuçin Avşar; Askin Seker; Zafer Orkun Toktaş; Süheyla Uyar Bozkurt; Ayse Nazli Başak; Türker Kılıç
Journal:  Vasc Cell       Date:  2012-10-01

6.  Procedure for the Isolation of Endothelial Cells from Human Cerebral Arteriovenous Malformation (cAVM) Tissues.

Authors:  Qiang Hao; Xiao-Lin Chen; Li Ma; Tong-Tong Wang; Yue Hu; Yuan-Li Zhao
Journal:  Front Cell Neurosci       Date:  2018-02-07       Impact factor: 5.505

7.  Simplex cerebral cavernous malformations with MAP3K3 mutation have distinct clinical characteristics.

Authors:  Ran Huo; Jie Wang; Ying-Fan Sun; Jian-Cong Weng; Hao Li; Yu-Ming Jiao; Hong-Yuan Xu; Jun-Ze Zhang; Shao-Zhi Zhao; Qi-Heng He; Shuo Wang; Ji-Zong Zhao; Yong Cao
Journal:  Front Neurol       Date:  2022-08-26       Impact factor: 4.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.